U.K. advises against OTC codeine use for all children
This article was originally published in The Tan Sheet
Executive Summary
The U.K. changes labeling for codeine-containing nonprescription drugs to recommend against use by children under 18 years old. The Medicines and Healthcare products Regulatory Agency 1noted the change Oct. 11 after a review by the advisory Commission on Human Medicines found "a lack of robust evidence supporting the efficacy of codeine in cough suppression in children." The CHM, working with its Pediatric Medicines Expert Advisory Group to review OTC cough and cold products for children, in 2009 recommended children under 6 years old not use antitussive codeine drugs (2"The Tan Sheet" March 9, 2009). After additional codeine safety and efficacy studies, the experts advised extending the recommendation to all children under 18. The change, which will appear in 2011 on labels for antitussive codeine drugs, follows MHRA's 2009 requirement for more prominent warnings about misuse of codeine nonprescription pain relief products (3"The Tan Sheet" Sept. 7, 2009, In Brief). All nonprescription codeine products in the U.K. remain available only from pharmacists
You may also be interested in...
U.K. To Move Kids’ Cough/Cold Drugs BTC, Redraws Age Recommendation
Manufacturers of pediatric cough/cold medicines sold in the U.K. have until March 2010 before the products must be sold behind the pharmacy counter, one of several measures to improve safe use
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.